Cytocom statera
WebSep 8, 2024 · According to the company, “Statera set aside a certain number of the total shares issuable in the Cytocom-Cleveland BioLabs merger to ensure that the former ImQuest Life Sciences stockholders... WebApr 10, 2024 · In 2024, Cytocom, announced the completion of its merger with CBLI which resulted in our receipt of 1,150,000 common shares of CBLI, reflecting our retained minority interest in Cytocom. Subsequent to the merger, CBLI adopted a new corporate name, "Statera BioPharma, Inc.", with the ticker symbol "STAB," effective on September 1, …
Cytocom statera
Did you know?
WebStatera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies. In 2024, Cleveland BioLabs merged with Cytocom, … WebOct 5, 2024 · Statera Biopharma is developing therapies designed to elicit directly within patients a robust and durable response of antigen-specific killer T cells and antibodies, thereby activating essential...
WebStatera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. WebAug 31, 2024 · FORT COLLINS, Colo., Aug. 31, 2024 — Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that …
WebStatera Biopharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. WebOct 27, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers...
WebUNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
WebAug 31, 2024 · Cytocom, Inc. Nichol Ochsner Senior V.P. Investor Relations and Corporate Communications (732) 754-2545 [email protected] Tiberend Strategic Advisors, Inc. Maureen McEnroe, CFA (Investors) (212) 375-2664 [email protected] Johanna Bennett (Media) (212) 375-2686 [email protected] sims 4 postcard legacyWebSep 28, 2024 · Cytocom issued the 125,000 shares of its common stock on March 4, 2024. Due to the fact that Cytocom did not have sufficient funds by January 25, 2024, it was unable to meet its payment obligations to Ira Gaines and the Gaines Trust due on that date. The $50,000 payment was made on June 9, 2024. rcf active speakersWebAug 31, 2024 · Cytocom is developing therapies designed to elicit directly within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby … sims 4 postcardsWebApr 27, 2024 · FORT COLLINS, Colo., April 27, 2024 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating next-generation immune therapies that focus... sims 4 postcards ccWebSep 8, 2024 · Statera is currently developing therapies designed to directly interact with antigen-specific killer T-cells and antibodies, which will then activate essential immune … rc-factory crack pitts miniWebJan 24, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers ... sims 4 post photo to fashion simstagram pathr. c. fabricators inc